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410 S.-C. Pan et al.characteristics resembling those of CA-MRSA or hospital-onset, healthcare-associated MRSA
(HA-MRSA-HO) infection.
Methods: A multicenter, retrospective study was conducted to analyze the clinical and micro-
biological data of patients with clinical isolates of MRSA from nine hospitals in Taiwan.
Results: In total, 203 patients with MRSA isolates, including 27 patients with CA-MRSA (13.3%), 59
with HA-MRSA-CO (29.1%), and 117 with HA-MRSA-HO (57.6%), were studied. Compared to HA-
MRSA-HO isolates, the CA-MRSA and HA-MRSA-CO isolates were associated with a higher propor-
tion of skin and soft tissue infections (81.8% and 65.3% vs. 40.5%,pZ 0.001 and pZ 0.002) aswell
as lesser rate of resistance to ciprofloxacin (33.3% and 50.9% vs. 74.4%, p< 0.001 and pZ 0.002),
gentamicin (44.4% and 64.4% vs. 84.6%, p< 0.001 and pZ 0.002), and trimethoprim/sulfa-
methoxazole (33.3% and 42.4% vs. 58.1%, pZ 0.02 and pZ 0.048), and a lower 30-day all-
cause mortality rate (7.4% and 0% vs. 20.9%, p< 0.001). Most of the CA-MRSA isolates were clas-
sified as staphylococcal cassette chromosome mec (SCCmec) type VT (11/27, 40.7%), whereas
most HA-MRSA-HO isolates were classified as SCCmec type III (66/117, 56.4%).
Conclusion: The CA-MRSA, HA-MRSA-CO, and HA-MRSA-HO clinical isolates significantly differed
in their clinical presentations and molecular characteristics.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is
a major pathogen causing nosocomial infection and is an
emerging cause of community-associated infection.1e3
Community-associated MRSA (CA-MRSA) has been recog-
nized as a novel pathogen group and has different charac-
teristics from nosocomial MRSA, including limited antibiotic
resistance, a different exotoxin gene profile (Pan-
toneValentine leukocidin), a different type of staphylo-
coccal cassette chromosome mec (SCCmec) gene, and
a different clinical spectrum.4,5 However, CA-MRSA clones
vary among different countries and regions.6e9
In Taiwan, several studies have attempted to compare
CA-MRSA and healthcare-associated MRSA (HA-MRSA). Most
such studies noted that CA-MRSA strains in Taiwan contain
a specific type of the SCCmec VT gene and possess Pan-
toneValentine leukocidin genes.10e13 However, these
studies were mostly limited to a single center, a specific
patient group (e.g., children, patients with end-stage renal
disease, or adults), or a specific disease pattern (e.g.,
bacteremia). Additionally, a new community-onset,
healthcare-associated MRSA (HA-MRSA-CO) infections have
been characterized in patients with community-onset
infection who have underlying conditions resulting in
frequent exposure to the healthcare system.14 Previous
studies have not thoroughly investigated whether HA-MRSA-
CO has characteristics resembling those of CA-MRSA or
hospital-onset, healthcare-associated MRSA (HA-MRSA-HO)
infection. This study used multicenter surveillance data of
clinical MRSA isolates to elucidate the clinical and micro-
biological characteristics of CA-MRSA, HA-MRSA-CO, and
HA-MRSA-HO isolates in Taiwanese patients.Materials and methods
Study participants
Patients with clinical MRSA isolates were enrolled in the
Taiwan Surveillance of Antimicrobial Resistance program IVand V (TSAR IV and V). In 1998, the Division of Clinical
Research, National Health Research Institute in Taiwan
initiated the TSAR program to survey antimicrobial resis-
tance in Taiwan and to promote national action in controlling
antimicrobial resistance. Isolates from inpatients and
outpatients of multiple medical centers and regional hospi-
tals across different parts of Taiwan were collected during
a 3-month period every 2 years. No duplicate isolates were
collected from a single patient. TSAR IV and V were con-
ducted in 2004 and 2006, respectively, at 10 medical centers
and 16 regional hospitals in Taiwan.
Variables and definitions
For each patient, the coinvestigator physicians at each
study site retrospectively reviewed the charts and recorded
data using a standardized data collection form. The data
collected included each patient’s age, sex, underlying
disease, and antimicrobial use (within 2 weeks). The
healthcare risk factors for MRSA included a history of MRSA
infection or colonization in the year preceding the culture,
hospitalization, invasive treatment (dialysis, chemo-
therapy, or surgery), residence in a long-term care facility
or respiratory care ward in the year preceding the culture,
and presence of an invasive device at time of
admission.15e17 Additionally, the presence of MRSA infec-
tion and the type of infection (as defined by the Centers for
Disease Control and Prevention, USA) were defined by
primary care physicians and reviewed by infectious disease
physicians during chart review.18 Colonization was defined
as having no symptoms or signs of infection at the site of
MRSA isolation, and no corresponding anti-MRSA antibiotics
were prescribed. The outcome was defined as 30-day all-
cause mortality and 30-day MRSA-related mortality.
Patients with HA-MRSA-CO had at least one healthcare
risk factor and a positive culture obtained within 48 hours
of hospital admission. Patients with HA-MRSA-HO had
a positive culture obtained 48 hours after hospital admis-
sion. CA-MRSA patients had no documented healthcare risk
factors and a positive culture obtained within 48 hours of
hospital admission.
Table 1 Baseline information of the enrolled patients.
Total
cases
(nZ 203)
Infection
cases
(nZ 166)
n (%) n (%)
Age (mean SD) 55.6 26.4 55.2 26.6
Sex
Male 138 (68.0) 115 (69.3)
Female 65 (32.0) 51 (30.7)
Transferred from
LTCF 15 (7.4) 11 (6.6)
RCW 4 (2.0) 3 (1.8)
Other hospitals 35 (17.6) 27 (16.5)
Underlying diseases
Diabetes mellitus 66 (32.5) 54 (32.5)
Renal insufficiency 34 (16.8) 28 (16.9)
Cardiovascular diseases 79 (40.0) 60 (63.1)
Gastrointestinal diseases 22 (10.8) 20 (12.1)
Malignancies 27 (13.3) 23 (13.9)
Neutropenia 1 (0.5) 1 (0.6)
Respiratory diseases 4 (2.0) 4 (2.40
Neurological diseases 30 (14.8) 23 (13.9)
Hepatobiliary diseases 47 (23.2) 37 (22.3)
Autoimmune diseases 12 (5.9) 8 (4.8)
Others 6 (3.0) 5 (3.0)
Previous hospitalization 120 (59.1) 100 (60.2)
Invasive procedures 32 (16.3) 24 (14.7)
Previous antibiotic use 105 (51.7) 89 (53.6)
Previous MRSA colonization
or infection in the
preceding year
65 (32.0) 51 (31.9)
CA-MRSA 27 (13.3) 23 (13.9)
HA-MRSA-CO 59 (29.1) 49 (29.5)
HA-MRSA-HO 117 (57.6) 94 (56.6)
Infection site
Respiratory tract infection e 27 (17.0)
Surgical site infection e 7 (4.4)
Skin and soft tissue infection e 86 (54.1)
Urinary tract infection e 10 (6.3)
Primary bloodstream infection e 18 (11.3)
Other e 12 (7.6)
30-day all-cause mortality 26 (13.0) 21 (12.7)
MRSA-related 30-day mortality 7 (3.5) 7 (4.2)
CA-MRSAZ community-associated methicillin-resistant Stap-
hylococcus aureus; HA-MRSA-COZ community-onset
healthcare-associated MRSA; HA-MRSA-HOZ hospital-onset
healthcare-associated MRSA; LTCFZ long-term care facility;
RCWZ respiratory care ward.
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Identification of S. aureus was confirmed by colony
morphology on trypticase soy agar supplemented with 5%
sheep blood (BBL Microbiology Systems, Cockeysville, MD,
USA), Gram stain, catalase test (as needed), and a positive
coagulase test (Bactistaph Latex Test; Remel, Lenexa, KS,
USA). MRSA strains were identified based on antimicrobial
susceptibility testing of all S. aureus isolates (described
below).
Susceptibility testing
The minimum inhibitory concentration of 12 antibiotics
(chloramphenicol, clindamycin, ciprofloxacin, erythro-
mycin, gentamicin, linezolid, oxacillin, rifampin, teicopla-
nin, tetracycline, trimethoprim/sulfamethoxazole, and
vancomycin) were determined by broth microdilution
following the guidelines of the Clinical and Laboratory
Standards Institute using custom-designed 96-well panels
(Sensititre; Trek Diagnostics, East Essex, England).19
DNA extraction
Bacterial DNA was extracted using the InstaGene matrix
(Bio-Rad Laboratories, Hercules, CA, USA) according to the
manufacturer’s protocol. Briefly, an isolated bacterial
colony was suspended in 1 mL autoclaved water in
a microfuge tube and then centrifuged for 1 minute at
6000g. The supernatant was removed, and the InstaGene
matrix (200 mL; Bio-Rad) was added to the pellet. The
mixture was vortexed, heated at 56C for 15 minutes,
vortexed again, heated at 100C for 8 minutes, and
centrifuged to pellet the matrix. The supernatant was used
in subsequent polymerase chain reactions.
Methods for typing the SCCmec element
The presence of SCCmec elements was determined by
polymerase chain reaction as previously described.20e22
Statistical methods
A chi-square test or Fisher’s exact test was used to examine
the associations of epidemiological variables with SCCmec
type, disease spectrum, and antimicrobial susceptibility.
A univariate analysis was performed to determine the asso-
ciation between significant variables and mortality among
MRSA-infected patients. Variables with a p value <0.2 were
included in themultivariate analysis andwere assessed using
logistic regression. We used STATA statistical software
version 9.0 (STATA, College Station, Texas, USA) for analysis.
Results
In this study, five medical centers and four regional hospi-
tals provided clinical isolates from TSAR IV and V programs
for 203 patients. There were 69 cases from TSAR IV and 134
cases from TSAR V. Of the 203 patients, 107 were from
medical centers and 96 were from regional hospitals.The percentage of isolates provided by each hospital
ranged from 8% to 33%. The general characteristics of these
patients are listed in Table 1. The mean age was 55.6 years
with a standard deviation of 26.4 years. The male/female
ratio was 138:65. According to the healthcare risk factors
and the timing of the cultures, 27 patients were classified
as having CA-MRSA (13.3%), 59 as having HA-MRSA-CO
(29.1%), and 117 as having HA-MRSA-HO (57.6%). The 30-
day all-cause mortality rate was 12.8%. Patients with HA-
MRSA-HO isolates had a significantly higher 30-day
412 S.-C. Pan et al.all-cause mortality rate (20.9%) than patients with CA-MRSA
and HA-MRSA-CO infections (7.4% and 0%, respectively;
p< 0.001).
Of the 203 patients, 166 patients had MRSA infection;
the remaining patients were only colonized. Among the 166
patients with MRSA infection, the most common site of
infection was the skin and soft tissues (86/166, 54.1%). The
30-day all-cause mortality rate among these 166 patients
was 12.7%, and the MRSA-related 30-day mortality rate was
4.2%. Among these 166 patients, those with HA-MRSA-HO
infection had a significantly higher 30-day all-cause
mortality rate (20.2%) than those with CA-MRSA and HA-
MRSA-CO infections (8.7% and 0%, respectively; pZ 0.002).
However, there was no significant difference in MRSA-
related 30-day mortality rate among patients with CA-
MRSA, HA-MRSA-CO, and HA-MRSA-HO (8.7%, 0%, and 5.3%,
respectively; pZ 0.29).
SCCmec typing
The SCCmec type pattern was significantly associated with
the epidemiologic classification of the CA-MRSA, HA-MRSA-
CO, and HA-MRSA-HO isolates (p< 0.001). Among the CA-
MRSA isolates, the most frequent SCCmec type was type
VT (40.7%), whereas SCCmec type III was most common in
HA-MRSA-CO and HA-MRSA-HO isolates (40.7% and 56.4%,
respectively). A significantly higher proportion of HA-MRSA-
HO isolates carried SCCmec type II or type III than did
CA-MRSA isolates (73.5% vs. 33.3%, p< 0.001) and HA-MRSA-
CO isolates (73.5% vs. 47.5%, pZ 0.001). On the otherTable 2 Number and percentage of MRSA isolates by epidemio
All MRSA isolates (nZ 203)
n (%)
CA-MRSA
(nZ 27)
HA-MRSA-CO
(nZ 59)
HA-MRSA-
(nZ 117)
SCCmec typing
II 0 (0) 4 (6.8) 20 (17.1
III 9 (33.3) 24 (40.7) 66 (56.4
IV 6 (22.2) 13 (22.0) 12 (10.3
VT 11 (40.7) 15 (25.4) 15 (12.8
V 1 (3.7) 3 (5.1) 4 (3.4)
Drug susceptibility (resistance rate)
Chloramphenicol 19 (70.4) 38 (64.4) 65 (55.6
Ciprofloxacin 9 (33.3) 30 (50.9) 87 (74.4
Clindamycin 23 (85.2) 50 (84.8) 108 (72.3
Erythromycin 24 (88.9) 55 (93.2) 114 (97.4
Gentamicin 12 (44.4) 38 (64.4) 99 (84.6
Linezolid 0 (0) 0 (0) 0 (0)
Rifampin 2 (7.4) 5 (8.5) 22 (18.8
SXT 9 (33.3) 25 (42.4) 68 (58.1
Tetracycline 20 (74.1) 49 (83.1) 85 (72.7
Teicoplanin 0 (0) 0 (0) 0 (0)
Vancomycin 0 (0) 0 (0) 0 (0)
CA-MRSAZ community-associated MRSA; HA-MRSA-COZ community-
healthcare-associated MRSA; SXTZ trimethoprim/sulfamethoxazole.
a p< 0.05 versus CA-MRSA.
b p< 0.05 versus HA-MRSA-CO.hand, CA-MRSA and HA-MRSA-CO isolates had a significantly
higher proportion of type IV, V, and VT than did HA-MRSA-
HO (Table 2).
Antibiotic susceptibility test
All 203 MRSA isolates were susceptible to vancomycin, tei-
coplanin, and linezolid and had varying levels of suscepti-
bility to other antibiotics. Most MRSA isolates were resistant
to erythromycin, clindamycin, and tetracycline (resistance
rates of 95.1%, 89.2%, and 75.9%, respectively). HA-MRSA-
HO isolates had significantly higher resistant rates to
ciprofloxacin, gentamicin, and trimethoprim/sulfamethox-
azole compared to CA-MRSA isolates (p< 0.001, p< 0.001,
and pZ 0.02, respectively) and HA-MRSA-CO isolates
(pZ 0.002, pZ 0.002, and pZ 0.048, respectively). In the
subgroup analysis of the HA-MRSA-HO isolates causing
infection, there was a significantly higher resistance rate to
ciprofloxacin and gentamicin (p< 0.001 and p< 0.001,
respectively) and a trend toward a higher resistance rate to
trimethoprim/sulfamethoxazole (pZ 0.051) compared
with the CA-MRSA isolates causing infection. Compared to
the HA-MRSA-CO isolates, the HA-MRSA-HO isolates causing
infection also had a significantly higher resistance rate to
ciprofloxacin and gentamicin (pZ 0.004 and pZ 0.005,
respectively) and a trend toward a higher resistance rate to
trimethoprim/sulfamethoxazole (pZ 0.059). There were
no significant differences in antibiotic susceptibility
between the CA-MRSA and HA-MRSA-CO isolates, regardless
of the presence of infection (Table 2).logic classification, SCCmec typing, and drug susceptibility.
MRSA isolates leading to infection (nZ 166)
n (%)
HO CA-MRSA
(nZ 23)
HA-MRSA-CO
(nZ 49)
HA-MRSA-HO
(nZ 94)
)a 0 (0) 3 (6.1) 16 (17.0)b
) 8 (34.8) 19 (38.8) 52 (55.3)
)b 6 (26.1) 10 (20.4) 10 (10.6)
)a,b 8 (34.8) 14 (28.6) 12 (12.8)a,b
1 (4.3) 3 (6.1) 4 (4.3)
) 16 (69.3) 33 (67.4) 51 (54.3)
)a,b 8 (34.8) 24 (49.0) 69 (73.4)a,b
) 20 (87.0) 43 (87.8) 88 (93.6)
) 21 (91.3) 46 (93.9) 92 (97.9)
)a,b 10 (43.5) 31 (63.3) 79 (84.0)a,b
0 (0) 0 (0) 0 (0)
) 2 (8.7) 4 (8.2) 18 (19.2)
)a,b 8 (34.8) 20 (40.8) 54 (57.5)
) 17 (73.9) 40 (81.6) 67 (71.3)
0 (0) 0 (0) 0 (0)
0 (0) 0 (0) 0 (0)
onset healthcare-associated MRSA; HA-MRSA-HOZ hospital-onset
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There were significant differences in the disease spectra of
infections with CA-MRSA, HA-MRSA-CO, and HA-MRSA-HO.
HA-MRSA-HO isolates caused a lower percentage of skin and
soft tissue infections (SSTIs) than did CA-MRSA isolates
(40.5% vs. 81.8%, pZ 0.001) and HA-MRSA-CO isolates
(40.5% vs. 65.3%, pZ 0.002). MRSA isolates carrying
SCCmec type II were associated with a significantly higher
percentage of respiratory tract infections (66.7% vs. 17.1%,
p< 0.001), whereas MRSA isolates carrying SCCmec type V
or VTwere associated with a significantly higher percentage
of SSTIs (87.8% vs. 43.4%, p< 0.001; Table 3).
Mortality
By univariate analysis, risk factors for 30-day all-cause
mortality among the 166 patients with MRSA infection
included older age; having been transferred from long-term
care facility, respiratory care ward, or other hospitals;
underlying renal insufficiency; cardiovascular disease;
malignancy; neurological disease; hospitalization within
the previous year; bacteremia or infection site other than
SSTIs; infection with SCCmec type III MRSA strain; no MRSA
colonization in the previous year; and infection with HA-
MRSA-HO (Table 4). By multivariate analysis, patients with
renal insufficiency or malignancy, SCCmec type III MRSA, or
HA-MRSA-HO infection had a higher 30-day all-cause
mortality rate (Table 5).
Discussion
In this study, we noted that different origins (CA-MRSA, HA-
MRSA-CO, or HA-MRSA-HO) led to different disease spectra,
different antibiotic resistance patterns, and different
mortality rates, and belonged to different SCCmec types.
Compared to HA-MRSA-HO, CA-MRSA and HA-MRSA-CO
isolates were associated with a higher proportion of SSTIs;
a lower resistance rate to ciprofloxacin, gentamicin, and
trimethoprim/sulfamethoxazole; and a lower 30-day all-
cause mortality rate. Most CA-MRSA isolates carried theTable 3 Number and percentage of MRSA isolates leading to cl
sification, and clinical condition.
Epidemiological classification
CA-MRSA
(nZ 23)
HA-MRSA-CO
(nZ 49)
HA-M
(nZ
Disease spectrum
Respiratory tract infection 1 (4.6) 6 (12.2) 20 (2
Surgical site infection 1 (4.6) 1 (2.0) 5 (5
Skin and soft-tissue infection 18 (81.8) 32 (65.3) 36 (4
Urinary tract infection 0 (0) 4 (8.2) 6 (6
Primary bloodstream infection 2 (9.1) 4 (8.2) 12 (1
Catheter-related infection 0 (0) 2 (4.1) 10 (1
CA-MRSAZ community-associated MRSA; HA-MRSA-COZ community-o
healthcare-associated MRSA; SCCmecZ staphylococcal cassette chrom
a p< 0.001 versus SCCmec type III.
b p< 0.05 versus SCCmec type III.
c p< 0.05 versus CA-MRSA and HA-MRSA-CO.SCCmec type VT gene, whereas most HA-MRSA-HO isolates
carried the SCCmec type III gene. HA-MRSA-CO more closely
resembled CA-MRSA with respect to disease spectrum,
antibiotic resistance pattern, mortality rate, and SCCmec
type.
Several single-center studies in Taiwan previously iden-
tified that SCCmec type VT was associated with CA-MRSA
strains and that SCCmec type III was associated with HA-
MRSA strains.11e13 The present study confirmed these asso-
ciations across different hospitals in Taiwan. The results
were also comparable to those among children in northern
Taiwan. 23 Although SCCmec type III was predominant among
HA-MRSA cases, 52.5% of HA-MRSA-CO isolates and 26.5% of
HA-MRSA-HO isolates carried SCCmec IV, V, or VT in our study.
This finding implies that CA-MRSA strains have already spread
into the hospitals, resulting in HA-MRSA-HO isolates that
carry the classical CA-MRSA SCCmec type. The result is
consistent with a previous study of MRSA in Taiwan.24
Furthermore, the mixed SCCmec typing among HA-MRSA-CO
isolates suggested that patients may acquire the infection
or colonization from the community, hospital, or other
healthcare facility.
On the other hand, previous studies in Taiwan demon-
strated that almost all CA-MRSA isolates carry the SCCmec
type IV, V, or VT gene.12,25,26 However, 33.3% of CA-MRSA
isolates carried SCCmec type III in our study. It is possible
that some cases of HA-MRSA were misclassified as CA-MRSA
cases due to the retrospective nature of the study.
However, we cannot exclude the possibility that the HA-
MRSA strains have spread from the hospital setting to the
community. This phenomenon must be closely followed and
further studied by prospective study setting.
The resistance patterns of CA-MRSA isolates in Taiwan
are noteworthy. In the United States, most CA-MRSA strains
were reported to be susceptible to erythromycin and clin-
damycin.4,5 In our study, however, the resistance rates to
these two antibiotics were universally high among CA-
MRSA, HA-MRSA-CO, and HA-MRSA-HO isolates. This was
also true among CA-MRSA isolates from children in
Taiwan.27 The high resistance rate to erythromycin may be
due to the numerous prescriptions for macrolides in
Taiwan, especially in outpatient clinics.28 The MRSA isolatesinical infection by epidemiologic classification, genetic clas-
, n (%) Genetic classification, n (%)
RSA-HO
94)
SCCmec II
(nZ 19)
SCCmec III
(nZ 79)
SCCmec IV
(nZ 26)
SCCmec V and
VT (nZ 42)
2.5) 12 (66.7)a 13 (17.1) 0 (0)b 2 (4.9)
.6) 1 (5.6) 5 (6.6) 1 (4.0) 0 (0)
0.5)c 0 (0)a 33 (43.4) 17 (68.0)b 36 (87.8)a
.7) 2 (11.1) 6 (7.9) 1 (4.0) 1 (2.4)
3.5) 2 (11.1) 10 (13.2) 4 (16.0) 2 (4.9)
1.2) 1 (5.6) 9 (11.8) 2 (8.0) 0 (0)b
nset healthcare-associated MRSA; HA-MRSA-HOZ hospital-onset
osome mec.
Table 4 Risk factors for 30-day all-cause mortality in patients with MRSA infection: univariate analysis.
Variables OR 95% CI p
Lower Upper
Age 1.020 1.006 1.059 0.015
Sex (male/female ratio) 1.422 0.490 4.126 0.517
Transferred from
LTCF 4.605 1.221 17.374 0.024
RCW 15.05 1.302 174.027 0.030
Other hospital 3.075 1.106 8.553 0.031
Underlying diseases
Diabetes mellitus 2.066 0.818 5.220 0.125
Renal insufficiency 6.364 2.368 17.102 <0.001
Cardiovascular diseases 4.261 1.611 11.269 0.003
Gastrointestinal diseases 1.245 0.332 4.675 0.745
Malignancies 6.964 2.498 19.412 <0.001
Respiratory diseases 7.474 0.994 56.204 0.051
Neurological diseases 2.988 1.021 8.743 0.046
Hepatobiliary diseases 1.9 0.704 5.126 0.205
Autoimmune diseases 0.979 0.004 8.377 0.984
Prehospitalization 4.667 1.316 16.548 0.017
Invasive procedures 2.733 0.939 7.954 0.065
Stay in ICU or not 2.560 0.958 6.841 0.061
Site of infection
RTI 0.536 0.116 2.472 0.424
SSTI 0.263 0.090 0.772 0.015
UTI 3.535 0.831 15.052 0.088
BSI 4.885 1.572 15.182 0.006
Others 4.367 1.174 16.244 0.028
SCCmec II 0.786 0.168 3.677 0.76
SCCmec III 5.621 1.801 17.541 0.003
SCCmec V and VT 0.283 0.063 1.274 0.100
Previous antibiotics exposure 2.112 0.817 5.460 0.123
MRSA colonization in the past year 0.197 0.044 0.883 0.034
CA-MRSA 0.617 0.134 2.844 0.535
HA-MRSA-HO 8.74 1.964 38.903 0.004
Note. For patients with risk factors, such as underlying disease with neutropenia, surgical site infection, SCCmec IV, or HA-MRSA-CO isolates,
there were no cases of 30-day mortality; thus, OR could not be calculated. BSIZ bloodstream infection; CA-MRSAZ community-associated
MRSA; CIZ confidence interval; HA-MRSA-HOZ hospital-onset healthcare-associated MRSA; LTCFZ long-term care facility; ORZ odds
ratio; RCWZ respiratory careward; RTIZ respiratory tract infection; SCCmecZ staphylococcal cassette chromosomemec; SSTIZ skin and
soft tissue infection; UTIZ urinary tract infection.
414 S.-C. Pan et al.carrying SCCmec type IV, V, or VT had high resistance rates
to chloramphenicol, clindamycin, erythromycin, and
tetracycline (86.2%, 85%, 87.5%, and 68.7%, respectively).
Thus, erythromycin and clindamycin should not beTable 5 Risk factors for 30-day all-cause mortality in
patients with MRSA infection, multivariate analysis.
Variables OR 95% CI p
Lower Upper
Renal disease 6.32 1.96 20.38 0.002
Malignancy 8.90 2.54 31.15 0.001
SCCmec III 4.93 1.30 18.69 0.019
HA-MRSA-HO 8.83 1.67 46.70 0.010
CIZ confidence interval; HA-MRSA-HOZ hospital-onset
healthcare-associated MRSA; ORZ odds ratio.considered for the empiric treatment of suspected CA-MRSA
infections in Taiwan. Compared to HA-MRSA-HO isolates,
CA-MRSA isolates in Taiwan had lower resistance rates to
gentamicin, ciprofloxacin, and trimethoprim/sulfamethox-
azole, which may be considered alternatives for the
treatment of CA-MRSA infection.
In the present study, there were no significant differ-
ences between the CA-MRSA and HA-MRSA-CO isolates with
respect to antibiotic resistance rate, mortality rate,
SCCmec type, and disease spectrum. Whether the clinical
presentation and molecular characteristics of HA-MRSA-CO
isolates more closely resembled those of CA-MRSA isolates
or HA-MRSA-CO isolates were not extensively studied
before. Klevens et al15 reported a population-based
surveillance study of invasive MRSA in the United States
and found that the clinical presentation of HA-MRSA-CO
isolates resembled that of HA-MRSA-HO isolates.
However, their study only included MRSA strains causing
Epidemiology of MRSA in Taiwan 415invasive infection. Therefore, many isolates from the SSTIs
were not included, and the results may not be represen-
tative of all MRSA infections. The differences in our results
may also be explained by the diversity of HA-MRSA-CO,
which may arise from CA-MRSA strains acquired in the
community by patients with associated healthcare risks,
from HA-MRSA strains acquired in the healthcare setting,
or from CA-MRSA strains acquired in the healthcare
setting.
The major limitation of this study is information bias due
to the retrospective nature of the data collection. Never-
theless, missing data are limited. However, the definition of
HA-MRSA established for data collection may have led to
misclassifications. Thus, we defined the risk factors for
healthcare-associated risk factors as previous MRSA infec-
tion or colonization in the year preceding the culture, since
it would be difficult to clearly identify previous MRSA
infection or colonization that occurred at other hospitals or
long before.
In conclusion, beyond nosocomial infection, CA-MRSA
strains have become an important component of MRSA
colonization and infection acquired in the healthcare
setting. They carry different clinical presentations and
molecular characteristics from the traditional HA-MRSA
strains. MRSA strains are spreading between the commu-
nity and hospitals, leading to mixed SCCmec types.
Furthermore, the antibiotic resistance pattern is becoming
more difficult to predict, which may complicate the
selection of empiric antibiotics for the treatment of MRSA
infections in the future.
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